目的:本研究旨在探讨帕罗西汀在治疗药物监测中血药浓度的相关影响因素,并建立我院帕罗西汀血药浓度参考区间,为临床安全、合理地使用帕罗西汀提供参考。方法:收集我院2021年1月至2023年12月服用帕罗西汀治疗抑郁症达稳态血药浓度患者...目的:本研究旨在探讨帕罗西汀在治疗药物监测中血药浓度的相关影响因素,并建立我院帕罗西汀血药浓度参考区间,为临床安全、合理地使用帕罗西汀提供参考。方法:收集我院2021年1月至2023年12月服用帕罗西汀治疗抑郁症达稳态血药浓度患者监测数据共272例统计学资料,考察性别、年龄、日剂量、民族、联合用药对帕罗西汀稳态谷浓度的影响,并建立帕罗西汀血药浓度参考区间,结合病例情况分析影响帕罗西汀稳态血药浓度的影响因素。结果:研究初步确定我院患者使用帕罗西汀治疗抑郁症时不同性别稳态血药浓度的参考区间。在相同日给药剂量下不同年龄、不同联合用药、不同民族患者帕罗西汀血药浓度的差异无统计学意义(P > 0.05)。但在30 mg/d和40 mg/d的剂量下,男性与女性的血药浓度存在显著差异(P Objective: The aim of this study is to explore the relevant influencing factors of paroxetine blood concentration in therapeutic drug monitoring, and to establish the reference interval of paroxetine blood concentration in our hospital, so as to provide reference for the safe and reasonable use of paroxetine in clinical practice. Methods: A total of 272 cases of statistical data were collected from January 2021 to December 2023 from our hospital to take paroxetine to treat depression up to steady-state blood concentration patients monitoring data, to investigate the influence of gender, age, daily dose, ethnicity, and combination of drugs on the steady-state trough concentration of paroxetine, and to establish the reference interval of paroxetine blood concentration, combined with the case situation to analyse the impact of the influence of the steady-state blood concentration of paroxetine factors. Results: The study preliminarily determined the reference intervals for steady state blood concentrations of different genders in the treatment of depression with paroxetine in our patients. The differences in paroxetine blood concentrations in patients of different ages, different combinations of medications, and different ethnicities at the same daily administered dose were not statistically significant (P > 0.05). However, there was a significant difference in blood concentrations between males and females at doses of 30 mg/d and 40 mg/d (P < 0.05). Conclusion: The reference intervals of steady state blood concentration of paroxetine in the treatment of depression in our hospital were 28.91~104.0 ng/mL in men and 33.46~124.39 ng/mL in women. Gender is an important factor affecting the steady state blood concentration of paroxetine, and the mean steady state blood concentration of women was higher than that of men under the condition of the same dosage of the drug administered, which may be related to gender Physiological differences in drug metabolism, such as body fat content, hormone levels and other factors affecting the distribution and clearance of the drug.展开更多
目的分析西安地区11~16岁健康青少年血清甲状腺功能特征并确立其指标参考范围,为临床诊疗提供理论依据。方法将空军军医大学第一附属医院(西京医院)2020年1月~2022年12月满足纳入标准的1378例11~16岁健康青少年作为研究对象,其中男性628...目的分析西安地区11~16岁健康青少年血清甲状腺功能特征并确立其指标参考范围,为临床诊疗提供理论依据。方法将空军军医大学第一附属医院(西京医院)2020年1月~2022年12月满足纳入标准的1378例11~16岁健康青少年作为研究对象,其中男性628例,女性750例。按不同年龄将研究对象分为三组:组1:11~<13岁433例;组2:13~<15岁425例;组3:15~≤16岁520例。分析11~16岁不同性别及不同年龄段血清甲状腺功能指标差异,建立各组参考范围,并选择99例符合纳入标准的11~16岁正常青少年进行验证。结果不同性别之间促甲状腺激素[TSH,2.56(1.80,3.63)μIU/ml vs 2.43(1.68,3.48)μIU/ml]及总甲状腺素[TT4,97.84(85.34,111.00)nmol/L vs98.20(87.16,111.23)nmol/L]比较,差异无统计学意义(Z=-1.881,-0.638,均P>0.05);游离甲状腺素[FT4,16.93(15.49,18.60)pmol/L vs 16.26(14.80,17.83)pmol/L]、游离三碘甲状腺原氨酸[FT3,6.21(5.66,6.80)pmol/L vs 5.59(4.98,6.19)pmol/L]、总三碘甲状腺原氨酸[TT3,2.24(1.96,2.55)pmol/L vs 2.04(1.78,2.34)nmol/L]比较,差异具有统计学意义(Z=-5.368,-11.994,-6.417,均P<0.01);不同年龄段之间的甲状腺功能各项指标间差异具有统计学意义(Z=10.649~261.003,均P<0.05)。该研究建立了不同年龄段、不同性别的甲状腺功能各项指标的参考范围,经99例标本验证血清甲状腺功能指标均在所建立的参考区间范围内。结论青少年机体各种激素分泌变化较大,甲状腺激素分泌受多种因素影响,不能完全依赖成人或厂家提供的参考范围诊断及治疗青少年甲状腺疾病,建立西安市11~16岁青少年甲状腺功能指标参考范围,为临床医生诊疗提供数据支持。展开更多
文摘目的:本研究旨在探讨帕罗西汀在治疗药物监测中血药浓度的相关影响因素,并建立我院帕罗西汀血药浓度参考区间,为临床安全、合理地使用帕罗西汀提供参考。方法:收集我院2021年1月至2023年12月服用帕罗西汀治疗抑郁症达稳态血药浓度患者监测数据共272例统计学资料,考察性别、年龄、日剂量、民族、联合用药对帕罗西汀稳态谷浓度的影响,并建立帕罗西汀血药浓度参考区间,结合病例情况分析影响帕罗西汀稳态血药浓度的影响因素。结果:研究初步确定我院患者使用帕罗西汀治疗抑郁症时不同性别稳态血药浓度的参考区间。在相同日给药剂量下不同年龄、不同联合用药、不同民族患者帕罗西汀血药浓度的差异无统计学意义(P > 0.05)。但在30 mg/d和40 mg/d的剂量下,男性与女性的血药浓度存在显著差异(P Objective: The aim of this study is to explore the relevant influencing factors of paroxetine blood concentration in therapeutic drug monitoring, and to establish the reference interval of paroxetine blood concentration in our hospital, so as to provide reference for the safe and reasonable use of paroxetine in clinical practice. Methods: A total of 272 cases of statistical data were collected from January 2021 to December 2023 from our hospital to take paroxetine to treat depression up to steady-state blood concentration patients monitoring data, to investigate the influence of gender, age, daily dose, ethnicity, and combination of drugs on the steady-state trough concentration of paroxetine, and to establish the reference interval of paroxetine blood concentration, combined with the case situation to analyse the impact of the influence of the steady-state blood concentration of paroxetine factors. Results: The study preliminarily determined the reference intervals for steady state blood concentrations of different genders in the treatment of depression with paroxetine in our patients. The differences in paroxetine blood concentrations in patients of different ages, different combinations of medications, and different ethnicities at the same daily administered dose were not statistically significant (P > 0.05). However, there was a significant difference in blood concentrations between males and females at doses of 30 mg/d and 40 mg/d (P < 0.05). Conclusion: The reference intervals of steady state blood concentration of paroxetine in the treatment of depression in our hospital were 28.91~104.0 ng/mL in men and 33.46~124.39 ng/mL in women. Gender is an important factor affecting the steady state blood concentration of paroxetine, and the mean steady state blood concentration of women was higher than that of men under the condition of the same dosage of the drug administered, which may be related to gender Physiological differences in drug metabolism, such as body fat content, hormone levels and other factors affecting the distribution and clearance of the drug.
文摘目的分析西安地区11~16岁健康青少年血清甲状腺功能特征并确立其指标参考范围,为临床诊疗提供理论依据。方法将空军军医大学第一附属医院(西京医院)2020年1月~2022年12月满足纳入标准的1378例11~16岁健康青少年作为研究对象,其中男性628例,女性750例。按不同年龄将研究对象分为三组:组1:11~<13岁433例;组2:13~<15岁425例;组3:15~≤16岁520例。分析11~16岁不同性别及不同年龄段血清甲状腺功能指标差异,建立各组参考范围,并选择99例符合纳入标准的11~16岁正常青少年进行验证。结果不同性别之间促甲状腺激素[TSH,2.56(1.80,3.63)μIU/ml vs 2.43(1.68,3.48)μIU/ml]及总甲状腺素[TT4,97.84(85.34,111.00)nmol/L vs98.20(87.16,111.23)nmol/L]比较,差异无统计学意义(Z=-1.881,-0.638,均P>0.05);游离甲状腺素[FT4,16.93(15.49,18.60)pmol/L vs 16.26(14.80,17.83)pmol/L]、游离三碘甲状腺原氨酸[FT3,6.21(5.66,6.80)pmol/L vs 5.59(4.98,6.19)pmol/L]、总三碘甲状腺原氨酸[TT3,2.24(1.96,2.55)pmol/L vs 2.04(1.78,2.34)nmol/L]比较,差异具有统计学意义(Z=-5.368,-11.994,-6.417,均P<0.01);不同年龄段之间的甲状腺功能各项指标间差异具有统计学意义(Z=10.649~261.003,均P<0.05)。该研究建立了不同年龄段、不同性别的甲状腺功能各项指标的参考范围,经99例标本验证血清甲状腺功能指标均在所建立的参考区间范围内。结论青少年机体各种激素分泌变化较大,甲状腺激素分泌受多种因素影响,不能完全依赖成人或厂家提供的参考范围诊断及治疗青少年甲状腺疾病,建立西安市11~16岁青少年甲状腺功能指标参考范围,为临床医生诊疗提供数据支持。